NCT01065246View on ClinicalTrials.gov

Safety Study of Second Intraperitoneal (I.P.) Infusion Cycle of Catumaxomab in Patients With Malignant Ascites

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

April 30, 2011

Study Completion Date

October 31, 2011

Conditions

Malignant Ascites Due to Epithelial Carcinoma

Interventions

DRUG

catumaxomab

4 intraperitoneal infusions within 11 days administered over 3 hours via an indwelling catheter at the following doses: 10 - 20 - 50 - 150 µg catumaxomab

Trial Locations (1)

13353

Charité Campus Virchow Clinic, Berlin